Kündgen, L.J.; Akhoundova, D.; Hoffmann, M.; Legros, M.; Shaforostova, I.; Seipel, K.; Bacher, U.; Pabst, T.
Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients. Cancers 2025, 17, 1565.
https://doi.org/10.3390/cancers17091565
AMA Style
Kündgen LJ, Akhoundova D, Hoffmann M, Legros M, Shaforostova I, Seipel K, Bacher U, Pabst T.
Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients. Cancers. 2025; 17(9):1565.
https://doi.org/10.3390/cancers17091565
Chicago/Turabian Style
Kündgen, Lea Jasmin, Dilara Akhoundova, Michele Hoffmann, Myriam Legros, Inna Shaforostova, Katja Seipel, Ulrike Bacher, and Thomas Pabst.
2025. "Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients" Cancers 17, no. 9: 1565.
https://doi.org/10.3390/cancers17091565
APA Style
Kündgen, L. J., Akhoundova, D., Hoffmann, M., Legros, M., Shaforostova, I., Seipel, K., Bacher, U., & Pabst, T.
(2025). Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients. Cancers, 17(9), 1565.
https://doi.org/10.3390/cancers17091565
